How does a heart failure clinic assess and manage a new patient with elevated left‑ventricular end‑diastolic pressure (~24 mm Hg), elevated pulmonary capillary wedge pressure (~18 mm Hg), preserved ejection fraction (~60 %), relative wall thickness 0.44, presenting with orthopnea, peripheral edema, and chronic dry cough?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Assessment and Management of Heart Failure with Preserved Ejection Fraction (HFpEF)

This patient has heart failure with preserved ejection fraction (HFpEF) confirmed by elevated filling pressures (LVEDP 24 mmHg, PCWP 18 mmHg), preserved EF (60%), and increased relative wall thickness (0.44), presenting with classic congestive symptoms—immediate treatment should focus on decongestion with loop diuretics and initiation of SGLT2 inhibitors (empagliflozin or dapagliflozin) as disease-modifying therapy. 1, 2

Initial Clinical Assessment

The heart failure clinic should immediately recognize this as HFpEF with elevated filling pressures based on:

  • Hemodynamic confirmation: LVEDP 24 mmHg and PCWP 18 mmHg both exceed normal thresholds (normal LVEDP <12 mmHg, PCWP <12 mmHg), definitively establishing elevated left ventricular filling pressures 3
  • Preserved systolic function: EF 60% meets HFpEF criteria (≥50%) 2
  • Structural abnormality: Relative wall thickness 0.44 indicates concentric remodeling (normal ≤0.42), suggesting hypertensive heart disease or hypertrophic response 4
  • Congestive symptoms: Orthopnea, fluid retention, and chronic dry cough represent volume overload requiring immediate intervention 5, 6

Key Diagnostic Confirmation Steps

The clinic should obtain:

  1. BNP or NT-proBNP levels to quantify disease severity and establish baseline for monitoring 2, 3

  2. Comprehensive echocardiography including:

    • E/e' ratio (average septal and lateral e') to assess filling pressures non-invasively 3
    • Left atrial volume index (LAVi) - values ≥34 mL/m² indicate chronically elevated pressures 4
    • LV mass index to quantify hypertrophy
    • Tissue Doppler velocities (e' <7 cm/s septal or <10 cm/s lateral suggests diastolic dysfunction) 3
  3. Exclude specific etiologies requiring targeted therapy 1:

    • Cardiac amyloidosis (technetium pyrophosphate scan if wall thickness disproportionate to hypertension history)
    • Hypertrophic cardiomyopathy (if unexplained severe hypertrophy)
    • High-output states (check thyroid function, assess for arteriovenous malformations)

Immediate Management: Decongestion

Start intravenous loop diuretics without delay - early intervention improves outcomes in decompensated heart failure 7:

  • Initial dose: If diuretic-naive, start furosemide 20-40 mg IV; if already on oral diuretics, use IV dose equal to or exceeding daily oral dose 5
  • Administration: Either intermittent boluses or continuous infusion are acceptable; titrate based on urine output and symptom relief 5
  • Monitoring: Daily weights, strict intake/output, daily electrolytes (potassium, creatinine, BUN) during active diuresis 7

Intensification Strategy if Inadequate Response

If congestion persists despite initial diuretic therapy 7:

  1. Increase loop diuretic dose
  2. Add second diuretic (metolazone 2.5-5 mg daily, or spironolactone 25 mg daily)
  3. Consider continuous furosemide infusion
  4. Add acetazolamide 500 mg IV if patient not on SGLT2 inhibitor (ADVOR trial showed superior decongestion) 6

Critical caveat: Avoid excessive diuresis causing hypotension or worsening renal function, as HFpEF patients are preload-dependent 8

Disease-Modifying Pharmacotherapy

First-Line: SGLT2 Inhibitors (Class I Recommendation)

Initiate empagliflozin 10 mg daily or dapagliflozin 10 mg daily before hospital discharge or at first outpatient visit 1, 2:

  • Evidence: EMPEROR-PRESERVED and DELIVER trials demonstrated 21% reduction in cardiovascular death or HF hospitalization 1
  • Mechanism: Reduces congestion, improves cardiac remodeling, benefits independent of diabetes status
  • Monitoring: Check renal function (can use if eGFR ≥20 mL/min/1.73m²), monitor for volume depletion initially

Second-Line: Mineralocorticoid Receptor Antagonists

Add spironolactone 25 mg daily (or eplerenone 25 mg daily if gynecomastia concerns) 1, 2:

  • Indication: Particularly if patient has hypertension, hypokalemia, or requires potassium supplementation
  • Monitoring: Check potassium and creatinine within 1 week, then monthly for 3 months
  • Contraindications: Potassium >5.0 mEq/L, eGFR <30 mL/min/1.73m²
  • Prefer MRA over potassium supplements for maintenance therapy 6

Consider: Angiotensin Receptor-Neprilysin Inhibitor (ARNI)

Sacubitril/valsartan may be considered if patient has:

  • LVEF closer to 50% (more benefit in HFmrEF range)
  • Elevated natriuretic peptides
  • Younger age with fewer comorbidities 1, 2

Start 24/26 mg twice daily, titrate to 97/103 mg twice daily as tolerated. Monitor blood pressure and renal function closely.

Blood Pressure and Comorbidity Management

Hypertension Control

Given the concentric remodeling (RWT 0.44), aggressive blood pressure control is essential:

  • Target: <130/80 mmHg 4
  • Agents: ACE inhibitors or ARBs are reasonable for hypertension control (though not proven to reduce HFpEF mortality) 8, 2
  • Beta-blockers: Use only if specific indication (prior MI within 3 years, angina, atrial fibrillation rate control) - may worsen exercise tolerance due to chronotropic incompetence 1

Address the Chronic Dry Cough

Investigate and treat potential causes:

  1. ACE inhibitor-induced: If on ACE inhibitor, switch to ARB
  2. Pulmonary congestion: Should improve with decongestion
  3. Pulmonary hypertension: Check tricuspid regurgitation velocity on echo; if elevated, consider right heart catheterization to differentiate post-capillary from pre-capillary pulmonary hypertension 9

Non-Pharmacological Management

Exercise Training (Class I Recommendation)

Prescribe supervised aerobic exercise program 5, 2:

  • Improves functional capacity and quality of life
  • Start with 20-30 minutes, 3-5 times weekly
  • Gradually increase intensity as tolerated

Weight Management

If BMI ≥30 kg/m²:

  • Target 5-10% weight loss through caloric restriction and exercise 1, 10
  • Consider referral to structured weight management program

Multidisciplinary Care Enrollment

Enroll in heart failure disease management program (Class I recommendation) 5, 2:

  • Reduces HF hospitalizations and mortality
  • Provides education on daily weights, dietary sodium restriction (<2-3 g/day), medication adherence
  • Facilitates early intervention for decompensation

Monitoring Strategy

Outpatient Follow-up Schedule

  1. Week 1-2: Assess diuretic response, check electrolytes and renal function
  2. Month 1: Titrate GDMT, reassess symptoms (NYHA class), repeat BNP
  3. Month 3: Comprehensive reassessment including repeat echocardiography to evaluate:
    • E/e' ratio improvement
    • Left atrial volume reduction
    • Response to therapy

Red Flags Requiring Urgent Reassessment

  • Worsening dyspnea despite therapy
  • Weight gain >2 kg in 3 days
  • Worsening renal function (creatinine increase >0.3 mg/dL)
  • Hypotension with symptoms
  • New arrhythmias (particularly atrial fibrillation)

Common Pitfalls to Avoid

  1. Over-diuresis: HFpEF patients are exquisitely sensitive to preload reduction; excessive diuresis causes hypotension and prerenal azotemia 8

  2. Assuming normal BNP excludes HFpEF: Obesity and chronic stable HFpEF may have "normal" BNP despite elevated filling pressures 11, 3

  3. Delaying SGLT2 inhibitor initiation: This is the only proven mortality-reducing therapy in HFpEF - start early 1, 2

  4. Using HFrEF dosing targets: HFpEF patients often cannot tolerate aggressive neurohormonal blockade due to blood pressure limitations

  5. Ignoring atrial fibrillation: If present, requires rate control (target <110 bpm at rest) and anticoagulation assessment 1

This algorithmic approach prioritizes immediate symptom relief through decongestion while simultaneously initiating evidence-based disease-modifying therapy with SGLT2 inhibitors, addressing the underlying pathophysiology of elevated filling pressures and concentric remodeling in this HFpEF patient.

References

Research

Left ventricular diastolic dysfunction in non-myocardial disorders.

European heart journal. Cardiovascular Imaging, 2024

Related Questions

Why does my chest pain and palpitations associated with heart failure with preserved ejection fraction (HFpEF) worsen during the night?
What are the United States guidelines for the diagnosis and treatment of heart failure with preserved ejection fraction (HFpEF)?
What are the clinical manifestations and diagnostic criteria for heart failure with preserved ejection fraction (HFpEF)?
What is another term for Diastolic Heart Failure, also known as Heart Failure with Preserved Ejection Fraction (HFpEF)?
What are the recommendations from the American Society of Echocardiography (ASE) guideline from July 2025 for the treatment of heart failure with preserved ejection fraction (HFpEF)?
How should a non-weight-bearing 5-year-old girl with a lateral ankle sprain and a negative preliminary X-ray be treated?
How should I manage post‑surgical pelvic‑floor muscle spasm that is easily triggered and interferes with parasympathetic function?
What are the appropriate indications, dosing guidelines, contraindications, and safety precautions for Pedicloryl (chloral hydrate) in pediatric patients?
What are the recommended fentanyl dosing guidelines for pediatric patients, including intravenous dose, procedural sedation dose, continuous infusion rate, and transdermal patch restrictions?
What laboratory tests should be ordered for a 69-year-old woman with fatigue and a history of hypothyroidism?
Why is my HbA1c (5.7%) classified as prediabetes when I have low triglycerides (46 mg/dL) and follow a low‑carbohydrate diet?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.